Dendrimer size effects on the selective brain tumor targeting in orthotopic tumor models upon systemic administration
Abstract Malignant gliomas are the most common and aggressive form of primary brain tumors, with a median survival of 15-20 months for patients receiving maximal interventions. Advances in nanomedicine have provided tumor‐specific delivery of chemotherapeutics to potentially overcome their off‐targe...
Saved in:
Main Authors: | Kevin Liaw (Author), Fan Zhang (Author), Antonella Mangraviti (Author), Sujatha Kannan (Author), Betty Tyler (Author), Rangaramanujam M. Kannan (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2020-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeted systemic dendrimer delivery of CSF‐1R inhibitor to tumor‐associated macrophages improves outcomes in orthotopic glioblastoma
by: Kevin Liaw, et al.
Published: (2021) -
Systemic administration of dendrimer N‐acetyl cysteine improves outcomes and survival following cardiac arrest
by: Hiren R. Modi, et al.
Published: (2022) -
Development of a novel glucose‐dendrimer based therapeutic targeting hyperexcitable neurons in neurological disorders
by: Anjali Sharma, et al.
Published: (2024) -
Systemic Dendrimer-Peptide Therapies for Wet Age-Related Macular Degeneration
by: Tony Wu, et al.
Published: (2023) -
Ultrasound inhibits tumor growth and selectively eliminates malignant brain tumor in vivo
by: Nitsa Buaron, et al.
Published: (2024)